Tarsus Pharmaceuticals Inc (TARS) - News Archive

Tarsus Pharmaceuticals Upsizes Public Offering to $125 Million Amid Strong Market ResponseIRVINE, Calif. March 12, 2025 Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company focusing on innovative eye...

IRVINE, Calif. In a significant development for investors and stakeholders alike, Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced the commencement of an underwritten public offering, initially aimed at raising...

In an ambitious update, Tarsus Pharmaceuticals delineated its strategic progress toward establishing ocular rosacea as a pivotal therapeutic opportunity within the eye care sector, targeting launch dates as early as 202...

Tarsus Pharmaceuticals Secures $200 Million Financing Commitment from Pharmakon, Bolstering Financial PositionIRVINE, Calif., April 23, 2024 - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company dedicated to addressi...

Tarsus Pharmaceuticals Announces Pricing of $100 Million Public OfferingIn a press release on March 1, 2024, Tarsus Pharmaceuticals, Inc. revealed the pricing of its underwritten public offering of 2,812,500 shares of c...

Tarsus Pharmaceuticals Inc., a pioneering biopharmaceutical company with a focus on transforming treatment options for patients, especially in the field of eye care, has announced the initiation of an underwritten publi...

Tarsus TP-05 Shows Promising Results in Phase 2a Trial: A Potential Breakthrough in Lyme Disease ProphylaxisLyme disease, caused by the spirochete bacterium Borrelia burgdorferi, is a significant public health concern i...

Tarsus Pharmaceuticals Reports Promising Results from Ersa Phase 2a Clinical Trial in Treating Meibomian Gland DiseaseTarsus Pharmaceuticals Inc. recently announced positive topline results from its Ersa Phase 2a clinic...